<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01503866</url>
  </required_header>
  <id_info>
    <org_study_id>402-C-1003</org_study_id>
    <nct_id>NCT01503866</nct_id>
  </id_info>
  <brief_title>A Phase I Study to Investigate the Absorption, Metabolism and Excretion in Healthy Male Subjects</brief_title>
  <official_title>A Phase 1 Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-Bardoxolone Methyl Following a Single Oral Dose Administration in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Reata Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Reata Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the absorption and excretion kinetics of&#xD;
      bardoxolone methyl and to determine and characterize metabolites present in plasma, urine and&#xD;
      feces in men following a single oral does or 20 mg of [14C]-bardoxolone methyl.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2011</start_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>area under curve</measure>
    <time_frame>0, 0.5, 1, 2, 3, 4, 6, 9, 12, 18, 24, 36, 48, 72, 96, and 120 hours after dose administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>radioactivity in plasma</measure>
    <time_frame>0, 0.5, 1, 2, 3, 4, 6, 9, 12, 18, 24, 36, 48, 72, 96, and 120 hours after dose administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>metabolites of ]14C]-bardoxolone methyl</measure>
    <time_frame>0, 0.5, 1, 2, 3, 4, 6, 9, 12, 18, 24, 36, 48, 72, 96, and 120 hours after dose administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentrations of cold bardoxolone methyl</measure>
    <time_frame>0, 0.5, 1, 2, 3, 4, 6, 9, 12, 18, 24, 36, 48, 72, 96, and 120 hours after dose administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>radioactivity in urine</measure>
    <time_frame>0 to 4, 4 to 8, 8 to 12, 12 to 24, 24 to 48, 48 to 72, 72 to 96, 96 to 120,120 to 144, 144 to 168, 168 to 192, 192 to 216, 216 to 240, 240 to 264, 264 to 288, and 288 to 312 hours after dose administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>radioactivity in feces</measure>
    <time_frame>0 to 4, 4 to 8, 8 to 12, 12 to 24, 24 to 48, 48 to 72, 72 to 96, 96 to 120,120 to 144, 144 to 168, 168 to 192, 192 to 216, 216 to 240, 240 to 264, 264 to 288, and 288 to 312 hours after dose administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>radioactivity in whole blood</measure>
    <time_frame>0, 0.5, 1, 2, 3, 4, 6, 9, 12, 18, 24, 36, 48, 72, 96, and 120 hours after dose administration</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>20 mg bardoxolone methyl</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bardoxolone methyl</intervention_name>
    <description>oral, single dose</description>
    <arm_group_label>20 mg bardoxolone methyl</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Males, between ages 18 and 45 years, inclusive;&#xD;
&#xD;
          -  Males will either be sterile or agree to use from Check-in (Day -1) until 45 days&#xD;
             following Clinic Discharge, i of the following approved methods of contraception: a&#xD;
             male condom with spermicide; a sterile sexual partner; use by female sexual partner of&#xD;
             an intrauterine device with spermicide; a female condom with spermicide; contraceptive&#xD;
             sponge with spermicide; an intravaginal system (eg, NuvaRing); a diaphragm with&#xD;
             spermicide;a cervical cap with spermicide; oral, implantable, transdermal, or&#xD;
             injectable contraceptives;&#xD;
&#xD;
          -  Within a BMI range 19 to 31 kg/m2, inclusive;&#xD;
&#xD;
          -  Willing and able to give written informed consent for study participation and provide&#xD;
             consent for access to medical data according to appropriate local data protection&#xD;
             legislation, allowing authorization to access medical records that describe events&#xD;
             captured in the endpoints;&#xD;
&#xD;
          -  Willing and able to cooperate with all aspects of the protocol;&#xD;
&#xD;
          -  at least 1 regular bowel movement per day.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participated in another clinical trial of an investigational drug (or a medical&#xD;
             device) within 30 days prior to study entry, or are currently participating in another&#xD;
             trial of an investigational drug (or a medical device);&#xD;
&#xD;
          -  Participated in a [14C]-study within the last 6 months prior to Check-in (Day -1) for&#xD;
             this study. The total exposure from this and any previous study must be within the&#xD;
             recommended levels considered safe (per 21 Code of Federal Regulations [CFR] 361.1&#xD;
             2010), for example, less than 5,000 mrem/year whole body exposure;&#xD;
&#xD;
          -  Exposure to significant radiation within 12 months prior to Check-in (Day -1);&#xD;
&#xD;
          -  Any condition possibly affecting absorption, distribution, metabolism, or excretion of&#xD;
             drugs that may confound the analyses conducted in this study;&#xD;
&#xD;
          -  Known hypersensitivity to any component in the formulation of the study drug,&#xD;
             bardoxolone methyl;&#xD;
&#xD;
          -  Evidence or history of or concurrent clinically significant allergic, hematological,&#xD;
             endocrine, immunological, renal, pulmonary, gastrointestinal, cardiovascular, hepatic,&#xD;
             psychiatric, or neurological disease that in the judgment of the Investigator could&#xD;
             potentially either pose a health risk to the subject during the study or influence the&#xD;
             study outcome;&#xD;
&#xD;
          -  Evidence of hepatic or biliary dysfunction including elevation of total bilirubin,&#xD;
             direct bilirubin, AST, ALT, GGT, lactate dehydrogenase, or alkaline phosphatase levels&#xD;
             to greater than the upper limit of normal;&#xD;
&#xD;
          -  Positive test results for human immunodeficiency virus type 1 or 2 antibody, hepatitis&#xD;
             B surface antigen, or hepatitis C virus antibody at Screening;&#xD;
&#xD;
          -  Any medical or dental procedure, no matter how minor, that is planned or anticipated&#xD;
             to occur during the conduct of the study;&#xD;
&#xD;
          -  History of drug or alcohol abuse or dependence within the last year;&#xD;
&#xD;
          -  Any vaccination within 30 days prior to Day 1 and throughout the study;&#xD;
&#xD;
          -  Use of or need for any systemic drug(s) including vitamins or herbal preparations&#xD;
             within 30 days prior to Day 1 or during the study;&#xD;
&#xD;
          -  Use of aspirin, non-steroidal anti-inflammatory drugs (NSAIDs), or acetaminophen&#xD;
             within 5 days prior to the ingestion of the study drug; use of aspirin or NSAIDs (but&#xD;
             not acetaminophen) will be allowed during confinement for isolated episodes of pain at&#xD;
             the discretion of the Investigator;&#xD;
&#xD;
          -  Donation or receipt of blood or blood components within 4 weeks prior to Screening;&#xD;
&#xD;
          -  Any diagnostic or intervention procedure requiring a contrast agent within the 30 days&#xD;
             prior to Screening;&#xD;
&#xD;
          -  Sustained systolic blood pressure &gt; 140 mmHg or &lt; 100 mmHg or a diastolic blood&#xD;
             pressure &gt; 95 mmHg at Screening or baseline measured after 5 minutes in a sitting&#xD;
             position;&#xD;
&#xD;
          -  A pulse rate at rest in a sitting position of &lt; 45 bpm or &gt; 100 bpm;&#xD;
&#xD;
          -  An abnormal Screening ECG which is interpreted by the Investigator to be clinically&#xD;
             significant;&#xD;
&#xD;
          -  Used tobacco- or nicotine-containing products (eg, cigarettes, cigars, chewing&#xD;
             tobacco, snuff) or products for smoking cessation 2 weeks prior to study drug&#xD;
             administration or during confinement to the Clinical Research Unit (CRU);&#xD;
&#xD;
          -  Treated with any investigational agent within 30 days before Check-in (Day -1) or 5&#xD;
             half-lives or twice the duration of biological effect of the previous investigational&#xD;
             drug (whichever is longer);&#xD;
&#xD;
          -  A positive history of drug abuse or positive results for screening test for drug(s) of&#xD;
             abuse, ethanol, amphetamines, barbiturates, cocaine, opiates, benzodiazepines,&#xD;
             cannabinoids, or urine cotinine (indicating active current smoking) at the Screening&#xD;
             or Check-in (Day -1) visits;&#xD;
&#xD;
          -  Poor peripheral venous access;&#xD;
&#xD;
          -  Deemed by the Investigator to be inappropriate for this study;&#xD;
&#xD;
          -  Any concurrent clinical conditions that in the judgment of the Investigator could&#xD;
             either potentially pose a health risk to the subject while involved in the study or&#xD;
             could potentially influence the study's outcome.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christine L Hale, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Covance Clinical Research Unit</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Covance Clinical Research Unit</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2011</verification_date>
  <study_first_submitted>December 22, 2011</study_first_submitted>
  <study_first_submitted_qc>December 31, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 4, 2012</study_first_posted>
  <last_update_submitted>December 31, 2011</last_update_submitted>
  <last_update_submitted_qc>December 31, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 4, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

